Skip to main content Accessibility help
×
Home

Can elevated concentrations of ALT and AST predict the risk of ‘recurrence’ of COVID-19?

  • L. Z. Chen (a1), Z. H. Lin (a2), J. Chen (a3), S. S. Liu (a4) (a5), T. Shi (a6) and Y. N. Xin (a1) (a2) (a4) (a5)...

Abstract

‘Recurrence’ of coronavirus disease 2019 (COVID-19) has triggered numerous discussions of scholars at home and abroad. A total of 44 recurrent cases of COVID-19 and 32 control cases admitted from 11 February to 29 March 2020 to Guanggu Campus of Tongji Hospital affiliated to Tongji Medical College Huazhong University of Science and Technology were enrolled in this study. All the 44 recurrent cases were classified as mild to moderate when the patients were admitted for the second time. The gender and mean age in both cases (recurrent and control) were similar. At least one concomitant disease was observed in 52.27% recurrent cases and 34.38% control cases. The most prevalent comorbidity among them was hypertension. Fever and cough being the most prevalent clinical symptoms in both cases. On comparing both the cases, recurrent cases had markedly elevated concentrations of alanine aminotransferase (ALT) (P = 0.020) and aspartate aminotransferase (AST) (P = 0.007). Moreover, subgroup analysis showed mild to moderate abnormal concentrations of ALT and AST in recurrent cases. The elevated concentrations of ALT and AST may be recognised as predictive markers for the risk of ‘recurrence’ of COVID-19, which may provide insights into the prevention and control of COVID-19 in the future.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Can elevated concentrations of ALT and AST predict the risk of ‘recurrence’ of COVID-19?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Can elevated concentrations of ALT and AST predict the risk of ‘recurrence’ of COVID-19?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Can elevated concentrations of ALT and AST predict the risk of ‘recurrence’ of COVID-19?
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

Author for correspondence: Y. N. Xin, E-mail: xinyongning@163.com

References

Hide All
1.Zhu, N et al. (2020) A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine 382, 727733.
2.Tan, WJ et al. (2020) A novel coronavirus genome identified in a cluster of pneumonia cases – Wuhan, China 2019–2020. China CDC Weekly 2, 6162.
3.World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020. https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Published 30 January 2020.
4.World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Published 11 March 2020.
5.World Health Organization. Coronavirus disease (COVID-19) outbreak. 2020. Available at https://www.who.int.
6.National Health Commission & National Administration of Traditional Chinese Medicine (2020) Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chinese Medical Journal 133, 10871095.
7.Ye, GM et al. (2020) Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. The Journal of Infection 80, e14e17.
8.Ravioli, S, Ochsner, H and Lindner, G (2020) Reactivation of COVID-19 pneumonia: a report of two cases. The Journal of Infection S0163–4453, 30279–6.
9.Loconsole, D et al. (2020) Recurrence of COVID-19 after recovery: a case report from Italy. Infection, 13.
10.Hoang, VT, Dao, TL and Gautret, P (2020) Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19. Journal of Medical Virology. doi: 10.1002/jmv.26056.
11.Cao, H et al. (2020) The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge. Journal of Medical Virology. doi: 10.1002/jmv.26017.
12.Yuan, J et al. (2020) PCR assays turned positive in 25 discharged COVID-19 patients. Clinical Infectious Disease, ciaa398.
13.Chen, M et al. (2020) Clinical characteristics of rehospitalized patients with COVID-19 in China. Journal of Medical Virology. doi: 10.1002/jmv.26002.
14.Jiang, ML et al. (2020) Recurrent PCR positivity after hospital discharge of people with coronavirus disease 2019 (COVID-19). The Journal of Infection 81, 147178.
15.Li, YJ et al. (2020) Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China. Journal of Medical Virology. doi: 10.1002/jmv.25905.
16.Xiao, AT, Tong, YX and Zhang, S (2020) False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. Journal of Medical Virology. doi: 10.1002/jmv.25855.
17.Lan, L et al. (2020) Positive RT-PCR test results in patients recovered from COVID-19. JAMA 323, 15021503.
18.Zhou, L, Liu, K and Liu, HG (2020) Cause analysis and treatment strategies of ‘recurrence’ with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital. Zhonghua Jie He He Hu Xi Za Zhi 43, 281284.
19.Guan, WJ et al. (2020) Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 382, 17081720.
20.Wang, DW et al. (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 10611069.
21.Chen, NS et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395, 507513.
22.Fan, ZY et al. (2020) Clinical features of COVID-19-related liver functional abnormality. Clinical Gastroenterology and Hepatology 18, 15611566.
23.Cai, QX et al. (2020) COVID-19: abnormal liver function tests. Journal of Hepatology S0168–8278, 30218-X.
24.Kukla, M et al. (2020) COVID-19 and liver dysfunction: a systematic review and meta-analysis of retrospective studies. Journal of Medical Virology. doi: 10.1002/jmv.26055.
25.Chen, T et al. (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091.
26.Zhang, C, Shi, L and Wang, FS (2020) Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 5, 428430.
27.Huang, CL et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395, 497506.
28.Chai, XQ et al. (2020) Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bio-Rxiv. https://doi.org/10.1101/2020.02.03.931766.
29.Guan, GW et al. (2020) Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi 28, 100106.
30.Wang, YJ et al. (2020) SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of Hepatology S0168–8278, 30294–4.
31.Li, J and Fan, JG (2020) Characteristics and mechanism of liver injury in 2019 coronavirus disease. Journal of Clinical and Translational Hepatology 8, 1317.
32.Cao, B et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. The New England Journal of Medicine 382, 17871799.
33.Prompetchara, E, Ketloy, C and Palaga, T (2020) Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pacific Journal of Allergy and Immunology 38, 19.
34.Feng, G et al. (2020) COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. Journal of Clinical and Translational Hepatology 8, 1824.
35.Hundt, MA et al. (2020) Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1827 patients in a major U.S. Hospital network. Hepatology. [published online ahead of print, 2020 Jul 29].

Keywords

Can elevated concentrations of ALT and AST predict the risk of ‘recurrence’ of COVID-19?

  • L. Z. Chen (a1), Z. H. Lin (a2), J. Chen (a3), S. S. Liu (a4) (a5), T. Shi (a6) and Y. N. Xin (a1) (a2) (a4) (a5)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.